DUBLIN–(BUSINESS WIRE)–The “Cluster Headache Syndrome – Pipeline Insight, 2022” report has been added to ResearchAndMarkets.com’s offering.
This “Cluster Headache Syndrome- Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cluster Headache Syndrome pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cluster Headache Syndrome pipeline landscape is provided which includes the disease overview and Cluster Headache Syndrome treatment guidelines. The assessment part of the report embraces, in depth Cluster Headache Syndrome commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cluster Headache Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cluster Headache Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Cluster Headache Syndrome.
Cluster Headache Syndrome Emerging Drugs Chapters
This segment of the Cluster Headache Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cluster Headache Syndrome Emerging Drugs
Eptinezumab: Lundbeck Seattle BioPharmaceuticals
Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. Currently, the drug is being developed in the Phase III stage of clinical trial evaluation for the treatment of Cluster Headache Syndromes.
SYNP-101: Ceruvia Lifesciences
SYNP-101 is a synthetic form of the naturally occurring compound, psilocybin, found in at least 200 species of mushrooms. Currently, the drug is being developed in the Phase I stage of clinical trial evaluation for the treatment of Cluster Headache Syndromes.
Cluster Headache Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Cluster Headache Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cluster Headache Syndrome
There are approx. 5+ key companies which are developing the therapies for Cluster Headache Syndrome. The companies which have their Cluster Headache Syndrome drug candidates in the most advanced stage, i.e. phase III include, Lundbeck Seattle BioPharmaceuticals.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Cluster Headache Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cluster Headache Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cluster Headache Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cluster Headache Syndrome drugs.
Cluster Headache Syndrome Report Insights
- Cluster Headache Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cluster Headache Syndrome Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cluster Headache Syndrome drugs?
- How many Cluster Headache Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cluster Headache Syndrome?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cluster Headache Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cluster Headache Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Lundbeck Seattle BioPharmaceuticals
- Ceruvia Lifesciences
Key Products
- Eptinezumab
- SYNP-101
- NYPRG101
For more information about this report visit https://www.researchandmarkets.com/r/3d3gsu
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
